Anti-hepatitis C virus T-Cell immunity in the context of multiple exposures to the virus

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Pfafferott, Katja ^f   Deshpande, Pooja ^b   McKinnon, Elizabeth ^a   Merani, Shahzma ^b   Lucas, Andrew ^a   Heckerman, David ^c   Mallal, Simon ^a,d   John, Mina ^a   Gaudieri, Silvana ^a,b   Lucas, Michaela ^a,b,e  

^a MURDOCH UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MICROSOFT RESEARCH   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; PEGINTERFERON ALPHA; RIBAVIRIN; HLA ANTIGEN; PEPTIDE;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; REVERSE GENETICS; VIRAL CLEARANCE; VIRUS IMMUNITY; ALLELE; CHEMISTRY; CHRONIC HEPATITIS C; COHORT ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; GENOMICS; HEPACIVIRUS; IMMUNOLOGY; VIROLOGY;

HEPATITIS C VIRUS;

ALLELES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; GENOMICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HLA ANTIGENS; HUMANS; MALE; PEPTIDES;

EID: 84939218226     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130420     Document Type: Article

References (41)

1. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology. 2008; 48(6):1746-52. Epub 2008/10/11. doi:10.1002/hep.22534PMID: 18844233.
2. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005; 436(7053):946-52. Epub 2005/08/19. doi: nature04079 [pii] doi:10.1038/nature04079PMID: 16107834.
3. Dazert E, Neumann-Haefelin C, Bressanelli S, Fitzmaurice K, Kort J, Timm J, et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest. 2009; 119(2):376-86. Epub 2009/01/14. 36587 [pii] doi:10.1172/JCI36587 PMID: 19139562; PubMed Central PMCID: PMC2631298.
4. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology. 2006; 43(3):563-72. Epub 2006/02/24. doi:10.1002/hep.21049 PMID: 16496339.
5. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med. 2004; 200(12):1593-604. Epub 2004/12/22. doi: jem.20041006 [pii] doi:10.1084/jem.20041006 PMID: 15611288; PubMed Central PMCID: PMC2212005.
6. Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: The evidence base 2002. Clin Exp Immunol. 2002; 128(2):195-203. Epub 2002/05/03. 1840 [pii]. PMID: 11985510; PubMed Central PMCID: PMC1906407.
7. John M, Heckerman D, James I, Park LP, Carlson JM, Chopra A, et al. Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol. 2010; 184(8):4368-77. doi:10.4049/jimmunol.0903745 PMID: 20231689; PubMed Central PMCID: PMC3011274.
8. Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol. 2006; 80 (22):11094-104. Epub 2006/10/31. 80/22/11094 [pii] doi:10.1128/JVI.00912-06 PMID: 17071929; PubMed Central PMCID: PMC1642167.
9. Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, et al. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology. 2009; 50(4):1017-29. Epub 2009/08/12. doi:10.1002/hep.23101 PMID: 19670417.
10. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004; 432(7018):769-75. doi:10.1038/nature03113 PMID: 15592417.
11. Carrington M, Walker BD. Immunogenetics of spontaneous control of HIV. Annu Rev Med. 2012; 63:131-45. Epub 2012/01/18. doi:10.1146/annurev-med-062909-130018 PMID: 22248321; PubMed Central PMCID: PMC3725592.
12. Hertz T, Nolan D, James I, John M, Gaudieri S, Phillips E, et al. Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol. 2011; 85(3):1310-21. Epub 2010/11/19. doi: JVI.01966-10 [pii] doi:10.1128/JVI.01966-10 PMID: 21084470; PubMed Central PMCID: PMC3020499.
13. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science. 2002; 296(5572):1439-43. Epub 2002/05/25. doi:10.1126/science.1069660 PMID: 12029127.
14. Timm J, Li B, Daniels MG, Bhattacharya T, Reyor LL, Allgaier R, et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology. 2007; 46(2):339-49. Epub 2007/06/15. doi:10.1002/hep.21702 PMID: 17559151.
15. Baker RI, Smith J, Eikelboom J, Leahy B, Kay I, Lavis N, et al. Hepatitis C genotypes in Australian haemophilia patients. Aust N Z J Med. 1996; 26(6):789-92. Epub 1996/12/01. PMID: 9028509.
16. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clin Infect Dis. 2013; 57 Suppl 2:80-9. doi:10.1093/cid/cit306 PMID: 23884071.
17. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995; 41(4):178-228. Epub 1995/01/01. PMID: 7890324.
18. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994; 152(1):163-75. Epub 1994/01/01. PMID: 8254189.
19. Listgarten J, Frahm N, Kadie C, Brander C, Heckerman D. A statistical framework for modeling HLAdependent T cell response data. PLoS Comput Biol. 2007; 3(10):1879-86. Epub 2007/10/17. 06- PLCB-RA-0286 [pii] doi:10.1371/journal.pcbi.0030188 PMID: 17937494; PubMed Central PMCID: PMC2014793.
20. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic acids research. 2008; 36(Web Server issue):W509-12. Epub 2008/05/09. doi:10.1093/nar/gkn202 PMID: 18463140; PubMed Central PMCID: PMC2447772.
21. Almeida CA, Roberts SG, Laird R, McKinnon E, Ahmed I, Pfafferott K, et al. Automation of the ELISpot assay for high-throughput detection of antigen-specific T-cell responses. J Immunol Methods. 2009; 344(1):1-5. Epub 2009/03/17. doi: S0022-1759(09)00072-6 [pii] doi:10.1016/j.jim.2009.02.007 PMID: 19285081; PubMed Central PMCID: PMC3818523.
22. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, et al. Comprehensive analysis of CD8 (+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol. 2002; 76(12):6104-13. Epub 2002/05/22. PMID: 12021343; PubMed Central PMCID: PMC136241.
23. Merani S, Petrovic D, James I, Chopra A, Cooper D, Freitas E, et al. Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak. Hepatology. 2011; 53(2):396-405. Epub 2011/01/20. doi:10.1002/hep.24076 PMID: 21246583; PubMed Central PMCID: PMC3044208.
24. Ruhl M, Knuschke T, Schewior K, Glavinic L, Neumann-Haefelin C, Chang DI, et al. CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology. 2011; 140 (7):2064-73. Epub 2011/03/08. doi: S0016-5085(11)00272-1 [pii] doi:10.1053/j.gastro.2011.02.060 PMID: 21376049.
25. Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, et al. Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol. 2008; 82(7):3438-51. doi:10.1128/JVI.01700-07 PMID: 18216107; PubMed Central PMCID: PMC2268453.
26. Hraber P, Kuiken C, Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology. 2007; 46(6):1713-21. Epub 2007/10/16. doi:10.1002/hep.21889PMID: 17935228.
27. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology. 2004; 40(1):108-14. Epub 2004/07/09. doi:10.1002/hep.20261 PMID: 15239092.
28. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature medicine. 2000; 6(5):578-82. doi:10.1038/75063 PMID: 10802716.
29. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology. 2004; 40(1):98-107. Epub 2004/07/09. doi:10.1002/hep.20291PMID: 15239091.
30. Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, et al. Molecular footprints reveal the impact of the protective HLA-A∗03 allele in hepatitis C virus infection. Gut. 2011; 60 (11):1563-71. Epub 2011/05/10. doi:10.1136/gut.2010.228403 PMID: 21551190; PubMed Central PMCID: PMC3184218.
31. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 1999; 10(6):661-71. Epub 1999/07/14. PMID: 10403641.
32. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, et al. Influence of HLA-C expression level on HIV control. Science. 2013; 340(6128):87-91. Epub 2013/04/06. doi:10.1126/science.1232685 PMID: 23559252; PubMed Central PMCID: PMC3784322.
33. Herzer K, Falk CS, Encke J, Eichhorst ST, Ulsenheimer A, Seliger B, et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol. 2003; 77(15):8299-309. Epub 2003/07/15. PMID: 12857899; PubMed Central PMCID: PMC165225.
34. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, Reddy S, et al. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B∗5703- restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J Virol. 2007; 81 (15):8346-51. Epub 2007/05/18. doi: JVI.00465-07 [pii] doi:10.1128/JVI.00465-07 PMID: 17507468; PubMed Central PMCID: PMC1951305.
35. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol. 2006; 80(7):3617-23. Epub 2006/03/16. 80/7/3617 [pii] doi:10.1128/JVI.80.7.3617-3623.2006 PMID: 16537629; PubMed Central PMCID: PMC1440414.
36. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol. 2007; 81(22):12382-93. Epub 2007/09/07. doi: JVI.01543-07 [pii] doi:10.1128/JVI.01543-07 PMID: 17804494; PubMed Central PMCID: PMC2169010.
37. Salloum S, Oniangue-Ndza C, Neumann-Haefelin C, Hudson L, Giugliano S, Aus Dem Siepen M, et al. Escape from HLA-B∗08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J Virol. 2008; 82(23):11803-12. Epub 2008/09/26. doi: JVI.00997-08 [pii] doi:10.1128/JVI.00997-08 PMID: 18815309; PubMed Central PMCID: PMC2583685.
38. Soderholm J, Ahlen G, Kaul A, Frelin L, Alheim M, Barnfield C, et al. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut. 2006; 55(2):266-74. Epub 2005/08/18. doi: gut.2005.072231 [pii] doi:10.1136/gut.2005.072231 PMID: 16105887; PubMed Central PMCID: PMC1856491.
39. Keane NM, Roberts SG, Almeida CA, Krishnan T, Chopra A, Demaine E, et al. High-avidity, high-IFNgamma- producing CD8 T-cell responses following immune selection during HIV-1 infection. Immunology and cell biology. 2012; 90(2):224-34. Epub 2011/05/18. doi:10.1038/icb.2011.34 PMID: 21577229; PubMed Central PMCID: PMC3173576.
40. Schulze Zur Wiesch J, Lauer GM, Timm J, Kuntzen T, Neukamm M, Berical A, et al. Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood. 2007; 110(5):1559-69. Epub 2007/05/04. doi: blood-2007-01-069583 [pii] doi:10.1182/blood-2007-01-069583 PMID: 17475911; PubMed Central PMCID: PMC1975840.
41. Harcourt GC, Lucas M, Sheridan I, Barnes E, Phillips R, Klenerman P. Longitudinal mapping of protective CD4+ T cell responses against HCV: Analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. Journal of viral hepatitis. 2004; 11(4):324-31. Epub 2004/07/03. doi:10.1111/j.1365-2893.2004.00516.x PMID: 15230855.